PLATFORM
Novel drug development platform
Multiple Business Models to Increase the success rate of novel drug development and diversify the risks
- PLATBIO’s Drug Development
-
- Combine drug candidates of partner company with PLATBIO’s proprietary novel target to develop high probability drug candidates
- Found 50+ novel targets from two indications (Pancreatic cancer and Ovarian cancer) using the PRIINT Platform, which possesses the highest number of anti-cancer targets among Korean companies
- Joint Development with Partner Companies
-
- Provide the research and development capabilities of PLATBIO with shared responsibilities and ownership of the drug candidates to increase the success rate
- Repositioning of the partner drug with PLATBIO’s translational research capabilities
- Pre-clinical/Clinical Translational Research/Clinical Test Consulting
-
- Services for domestic and foreign sponsors
- Target customer preclinical/clinical success
- Cases of transitioning a customer to a partner for joint development
- Orthotopic transplant model/Clinical translational research
- Regimen development/Indication expansion
- Reentry Reposition Consulting
- Reverse Translation
- Multiple pipeline Models to Increase
-
- One or more PLATBIO’s own pipelines annually
- Two or more joint
pipelines annually
- Stable revenue
- Cases of transitioning a
customer to a partner for joint development
Proven Research and Development Capability 50+ Anti-Cancer Novel Targets
- Drug development
-
-
- Joint development
-
-
Clinical Trials for Phase I, Phase II or Phase III + License Out (NRDO or Big Pharmas)